Intraoperative Coeliac Plexus Alcohol Neurolysis Along With Frey's Procedure for a Better Pain Relief
- Conditions
- Chronic Calcific Pancreatitis
- Interventions
- Procedure: Placebo celiac plexus injection using salineProcedure: celiac plexus neurolysis using absolute alcoholProcedure: Frey's procedure
- Registration Number
- NCT02735330
- Lead Sponsor
- Madras Medical College
- Brief Summary
To study the effect of Intra operative Coeliac plexus alcohol neurolysis combined with Frey's procedure for effective pain relief in patients with Chronic Calcific Pancreatitis in a single centre setting with a Randomized Controlled Trial.
- Detailed Description
165 consecutive CCP patients admitted in our surgical gastro enterology department since January 2013 were screened for eligibility. 29 patients were excluded (28 were not meeting the inclusion criteria and 1 patient intra operatively found to have disseminated malignancy). After exclusion 136 patients were included in our study. They were randomized in to 2 groups, one group was treated by Frey's procedure with NCPB (Group-I) and the other by Frey's procedure with saline as placebo (Group-II). Method of Study is a randomized, double- blind, placebo- controlled, parallel arm, superiority trial.
Randomization was done at the time of surgery using random number table created with computerized software by a statistician not involved in this study.
Blinding and masking was done by using pre numbered containers having filled with either absolute alcohol or saline according to the randomization chart which was then kept sealed by an office staff until the end of the study. Both subjects and response assessor were blinded.
Data collection:
The preoperative baseline details such as etiology, morphology, associated complications and VAS pain score, Izbicki pain score, weight loss, insulin requirement, LFT (liver function tests), serum amylase \& lipase, fasting sugar\& fecal elastase were collected on admission.
Additional procedures, presence of peripancreatic inflammatory changes (fibrosis) as evidenced by difficult Kocherisation and plasted capsule and intra-operative complications were noted during surgery.
Short term follow up details including pain relief measured by VAS score \&Izbicki pain score, analgesic consumption, weight gain, improvement in steatorrhoea (Fecal elastase\>200 µg/g of stool \& subjective reduction in foul smelling oily diarrhea), diabetic status (fasting glucose, GTT, HgbA1c, insulin\& oral hypoglycemic agents requirement), mortality and morbidity were noted.
Follow up details were collected every 3 months as outpatient basis. Standard questionnaire format of SF 12 Version-2 was used for QOL assessment every 6 months in a face to face interview.
Statistical analysis was performed in SPSS version 20. Continuous variables were presented as mean, standard deviation and 95% confidence interval; categorical variables were presented as frequencies. The chi-square test and the Fisher exact test were used to analyze categorical variables. The unpaired Student t test was used to analyze continuous variables. P value \<0.05 was considered statistically significant. Factors found significant on univariate logistic regression analysis were incorporated in to the multivariate logistic regression analysis for odds ratio with 95% confidence intervals to analyze the significant factors affecting the outcome of surgery.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 136
- Consecutive chronic calcific pancreatitis admitted in our institute since 2013 january with age group between 13 to 65 years with Visual analogue scale (VAS) pain score of more than 7 and those who have quit alcohol & smoking for at least 6 months are included in our study.
- Patients with mild to moderate pain score (VAS pain score 1-7), continuous substance abuse, severe comorbid illness are excluded from study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GROUP 2 Placebo celiac plexus injection using saline 68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline GROUP 1 celiac plexus neurolysis using absolute alcohol 68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol GROUP 1 Frey's procedure 68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol GROUP 2 Frey's procedure 68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
- Primary Outcome Measures
Name Time Method Pain relief measured by Visual Analogue Scale up to 5 years Short term (2 years) and long term(5 years) score at follow up at out patient clinic or over phone.
- Secondary Outcome Measures
Name Time Method Number of patients with improvement in endocrine function as measured by Fasting glucose of < 130 and HbA1c level of <6.5% up to 5 years and reduction in dosage of insulin (iu) \& oral hypoglycemic agents (milli gm) when compared to preoperative levels- at out patient clinic
Number of patients with improvement or worsening in exocrine function as measured by the estimation of fecal elastase >200 µg/g of stool or <200 µg/g of stool respectively at out patient clinic. up to 5 years Analgesics intake up to 5 years Dosage and frequency of intake of both NSAIDs and opioid analgesics intake are noted at out patient clinic or over phone.
Weight gain in kg measured at out patient clinic up to 5 years Quality of life up to 5 years Using SF 12 V2 (Tamil and english version-Optuminsight Life Sciences) in a face to face (written form) interview at out patient clinic
Number of patients with worsening in endocrine function as measured by abnormal laboratory values like Fasting glucose >130 and HbA1c >6.5 up to 5 years and increased dosage of insulin (IU)\& oral hypoglycemic agents(milli gms) requirement when compared to preoperative levels at out patient clinic
Number of patients with abnormal lab values like Fasting glucose of >126 mg/dl or blood glucose level of >200 after a standard glucose tolerance test (GTT) in equivocal cases. up to 5 years